The use of patient-derived primary cell cultures in cancer preclinical assays, including drug screens and genotoxic studies, has increased in recent years. However, their translational value is constrained by several limitations, including variability that can be caused by the culture conditions.

Last updated on: 20-07-2023 - 15:05

Contact: Ahmad Najem
Organisation: Institut Jules Bordet
Status: Published in peer reviewed journal